You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Multi-cohort

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer Trial (KN046, regorafenib)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Aug 2, 2023

Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Pancreatic Carcinoma Trial in Tianjin (Surufatinib, Sintilimab)

Recruiting
  • Neuroendocrine Tumor Grade 3
  • +2 more
  • Tianjin, Tianjin, China
    Rui Liu
Nov 17, 2022

Advanced Solid Tumor Trial in Changsha (IBI363)

Not yet recruiting
  • Advanced Solid Tumor
  • Changsha, Hunan, China
    Yongchang Zhang
Oct 12, 2023

Gastric Cancer, Gastroesophageal-junction Cancer Trial (IBI315, Oxaliplatin, Capecitabine)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • (no location specified)
Nov 2, 2022

Colorectal Cancer, Pancreatic Cancer Trial in Hangzhou (Bemalenograstim alfa)

Not yet recruiting
  • Colorectal Cancer
  • Pancreatic Cancer
  • Bemalenograstim alfa
  • Hangzhou, China
    the Second Affiliated Hospital of Medical College of Zhejiang Un
Nov 14, 2023

Solid Tumor Trial (ZGGS18 for Injection)

Not yet recruiting
  • Solid Tumor
  • ZGGS18 for Injection
  • (no location specified)
Oct 13, 2022

PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only

Not yet recruiting
  • PARP Inhibitor for Esophageal Squamous Cell Carcinoma
  • Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
  • (no location specified)
Sep 24, 2023

Colon Cancer, Neoadjuvant Therapy, Immunotherapy Trial in Guangzhou (Envafolimab, CAPEOX)

Recruiting
  • Colon Cancer
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Aug 26, 2023

NSCLC Trial in China (BBP-398, osimertinib)

Recruiting
  • NSCLC
  • Beijing, Beijing, China
  • +4 more
Sep 4, 2023

Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)

Not yet recruiting
  • Breast Neoplasms
  • Guangzhou, Gangdong, China
    Sun-yat sen university cancer center
Jul 30, 2023

Hepatocellular Carcinoma Trial (Atezolizumab, Bevacizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Oct 18, 2023

Colorectal Cancer, GIST Trial (DCC-3116, Ripretinib, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • GIST
  • (no location specified)
Jul 14, 2023

A Non-interventional Multi-country Cohort Study to Assess Safety

Not yet recruiting
  • Pregnancy
  • +2 more
    • (no location specified)
    May 4, 2023

    Potential Chemoprevention Drugs in Recurrent Hepatocellular

    Recruiting
    • Hepatocellular Carcinoma Recurrent
    • Surgery
    • No intervention for research purpose
    • Taichung, Taiwan
      China Medical University Hospital, Department of Surgery
    Aug 5, 2023

    Oncolytic Virotherapy Trial in St. Petersburg (Double Recombinant Vaccinia Virus VV-GMCSF-Lact)

    Recruiting
    • Oncolytic Virotherapy
    • Double Recombinant Vaccinia Virus VV-GMCSF-Lact
    • St. Petersburg, Russian Federation
      N.N. Petrov National Medical Research Center of Oncology
    May 11, 2022

    Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

    Not yet recruiting
    • Non Squamous Non Small Cell Lung Cancer
    • EGFR Positive Non-small Cell Lung Cancer
    • Toripalimab plus Chemotherapy
    • (no location specified)
    Jul 28, 2023

    Healthy Trial (TYRA-300-B01)

    Not yet recruiting
    • Healthy
    • (no location specified)
    Aug 17, 2023

    Advanced Lung Cancer, Ovarian Cancer Trial in Changsha, Yangzhou, Shanghai (AL2846 capsule)

    Recruiting
    • Advanced Lung Cancer
    • Ovarian Cancer
    • AL2846 capsule
    • Changsha, Hunan, China
    • +3 more
    Apr 4, 2023

    Metastatic Liver Cancer Trial in Shanghai (HAIC?Bevacizumab?Camrelizumab)

    Not yet recruiting
    • Metastatic Liver Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Dec 7, 2022

    Head and Neck Squamous Cell Carcinoma Trial (Pembrolizumab, Cisplatin, Paclitaxel-albumin)

    Not yet recruiting
    • Head and Neck Squamous Cell Carcinoma
    • (no location specified)
    Oct 25, 2023

    Relapsed/Refractory Trial in Santa Fe (Tafasitamab, Lenalidomide, Tazemetostat)

    Recruiting
    • Relapsed/Refractory
    • Santa Fe, California
      California Cancer Associates For Research And Excellence, cCARE
    Feb 23, 2022

    Proteus Syndrome Trial run by the NHGRI (MK-7075 (miransertib))

    Recruiting
    • Proteus Syndrome
    • MK-7075 (miransertib)
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Nov 19, 2022

    Multi-center Acute Severe Ulcerative Colitis Cohort Study

    Recruiting
    • Ulcerative Colitis
    • Standard of care
    • Baltimore, Maryland
      Joanna Melia
    Jan 4, 2023

    The Jinling Cohort

    Recruiting
    • Cancer
    • +2 more
    • MERCURY test, health questionnaires and annual routine physical exams
    • Nanjing, Jiangsu, China
    • +1 more
    Aug 23, 2023

    Frailty, Fall, Sarcopenia Trial in Taipei (Multidomain frailty prevention method, Regular follow up)

    Recruiting
    • Frailty
    • +2 more
    • Multidomain frailty prevention method
    • Regular follow up
    • Taipei, Taiwan
      Kun-Pei Lin
    Feb 7, 2023